Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald’s, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs – at […]
Read full article at https://wccftech.com/around-42-percent-of-those-aged-20-and-above-in-the-us-are-obese-yet-glp-1-weight-loss-drugs-are-not-covered-by-99-percent-of-affordable-care-act-aca-marketplace-plans/
